Liquidia Corp has reached a pivotal settlement agreement with United Therapeutics Corporation (UTC) that addresses ongoing patent infringement litigations. This agreement, finalized on October 13, 2026, is crucial for Liquidia as it allows the company to continue marketing its pulmonary arterial hypertension treatment, YUTREPIA (treprostinil) inhalation powder. The settlement is expected to reshape the competitive landscape in the pharmaceutical preparations sector.
Liquidia Corp, based in Morrisville, North Carolina, operates under the SIC code 2834, which encompasses pharmaceutical preparations. The company trades on the Nasdaq under the ticker symbol LQDA. Recent filings include various reports detailing financial activities and litigation updates, with the most recent 8-K filed on October 14, 2026.
The SEC filing reveals that the settlement agreement resolves multiple patent infringement litigations involving U.S. Patent Nos. 11,824,327, 11,357,782, and 10,989,494, as well as trade secret and breach of contract claims pending in the North Carolina Business Court. Liquidia will continue to market YUTREPIA but must amend the product label to remove references to treating pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company will also cease all marketing activities related to this indication.
Financially, Liquidia is obligated to make significant payments to UTC. The company will pay a net amount of $175 million within 30 business days following the effective date of the settlement. Additionally, Liquidia will make two further payments totaling $145.4 million, due by January 31, 2027, and April 30, 2027. The agreement also includes mutual releases of claims between the parties, contingent upon the completion of these payments and other conditions.
This settlement not only affects Liquidia but also has implications for its competitors in the pharmaceutical preparations industry. The resolution of these litigations may alter market dynamics, particularly for companies involved in similar treatments for pulmonary arterial hypertension. The agreement also requires Liquidia to settle related litigation with Sandoz and other parties, further influencing its operational landscape.
Looking ahead, Liquidia's next steps involve fulfilling the financial obligations outlined in the settlement and securing FDA approval for the amended product label. The filing does not specify what happens next beyond these requirements, leaving stakeholders to await further developments.